CSPC PHARMACEUTICAL GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.6 HKD | +1.23% |
|
+14.38% | -9.09% |
| 26/04 | CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S | CI |
| 24/04 | CSPC Pharmaceutical's EBT Buys 8.5 Million Shares | MT |
| Sales 2024 * | 37.59B 4.8B 400B | Sales 2025 * | 40.69B 5.2B 433B | Capitalization | 78.17B 9.99B 833B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.13B 911M 75.92B | Net income 2025 * | 7.69B 982M 81.92B | EV / Sales 2024 * | 1.62 x |
| Net cash position 2024 * | 17.38B 2.22B 185B | Net cash position 2025 * | 23.08B 2.95B 246B | EV / Sales 2025 * | 1.35 x |
| P/E ratio 2024 * |
11
x | P/E ratio 2025 * |
10.2
x | Employees | 23,500 |
| Yield 2024 * |
2.89% | Yield 2025 * |
3.16% | Free-Float | 70.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.23% | ||
| 1 week | +14.38% | ||
| Current month | +7.32% | ||
| 1 month | +3.94% | ||
| 3 months | +10.18% | ||
| 6 months | +9.82% | ||
| Current year | -9.09% |
1 week
5.81
6.64
1 month
5.656.64
Current year
5.567.37
1 year
5.208.25
3 years
5.2012.68
5 years
5.2012.68
10 years
2.7713.93
| Managers | Title | Age | Since |
|---|---|---|---|
Cui Long Zhang
CEO | Chief Executive Officer | 55 | 01/96/01 |
Dong Chen Cai
CHM | Chairman | 70 | 01/98/01 |
Hao Jiang
BRD | Director/Board Member | 41 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 70 | 01/98/01 |
Cheuk Kin Law
BRD | Director/Board Member | 61 | 08/21/08 |
Kin Man Chak
BRD | Director/Board Member | 58 | 01/05/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.05% | 2 M€ | -16.59% | - | |
| 2.02% | 4 M€ | -27.92% | ||
| 1.07% | 3 M€ | -0.84% | - | |
| 0.99% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 6.6 | +1.23% | 47,181,080 |
| 25/24/25 | 6.52 | +4.82% | 67,812,240 |
| 24/24/24 | 6.22 | +2.81% | 40,605,810 |
| 23/24/23 | 6.05 | +0.83% | 31,703,370 |
| 22/24/22 | 6 | +3.99% | 42,020,550 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
CSPC Pharmaceutical Group Ltd. specializes in the development, manufacture and marketing of pharmaceutical products. Net sames by category of products break down as follows:
- drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%);
- vitamin C (10.1%);
- antibiotics (6.2%);
- other (5%): including anhydrous and raw caffeine.
Net sales are distributed geographically as follows: China (82.8%), Asia (7.2%), Europe (4.6%), the Americas (4.4%) and others (1%).
Sector
Pharmaceuticals
Calendar
22/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
6.6
HKD
Average target price
9.348
HKD
Spread / Average Target
+41.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.09% | 9.99B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 1093 Stock
